Olatoyosi Odenike

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Nitin Jain, Emily Curran, Neil M. Iyengar et al. · Clinical Cancer Research · 2013 · 111 citations · Full text

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Guillermo Garcia‐Manero, Aaron D. Goldberg, Eric S. Winer et al. · The Lancet Haematology · 2023 · 82 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +9

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study

Brittany Knick Ragon, Olatoyosi Odenike, Maria R. Baer et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 64 citations · Full text

Hematological Malignancy, Inhibitor Trametinib, Medicine +7

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, Elias Jabbour, Karen Yee et al. · Blood · 2013 · 33 citations

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein et al. · Journal of Clinical Oncology · 2018 · 32 citations

Pharmacotherapy, Midh Inhibitors, Translational Pharmacology +17